XML 35 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Financial instruments disclosures (Tables)
6 Months Ended
Jun. 30, 2018
Disclosure Of Financial Instruments [Abstract]  
Summary of fair value of financial instruments

The carrying amounts and fair values of all of the Group’s financial instruments which are not carried at an amount which approximates their fair value at 30 June 2018 and 31 December 2017 are shown in the following table. The fair values of the Group's cash and loans to equity accounted units approximate their carrying values as a result of their short maturity or because they carry floating rates of interest.

 

 

 

 

 

30 June 2018

 

31 December 2017

 

 

 

 

Carrying

 

Fair

 

Carrying

 

Fair

 

 

 

 

value

 

value

 

value

 

value

 

 

 

 

US$m

 

US$m

 

US$m

 

US$m

Short term borrowings

(428)

 

(428)

 

(552)

 

(552)

Medium and long term borrowings

(12,485)

 

(13,806)

 

(14,624)

 

(16,385)

The table below shows the financial instruments carried at fair value by valuation method in accordance with IFRS 9 at 30 June 2018:

 

 

 

 

 

 

 

 

 

 

 

Not held

 

 

Total

 

Level 1(a)(i)

 

Level 2(b)(i)

 

Level 3(c)(i)

 

at fair value

 

 

US$m

 

US$m

 

US$m

 

US$m

 

US$m

Assets

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents(d)

 

5,989

 

3,130

 

-

 

-

 

2,859

Investments in equity shares and funds

 

141

 

19

 

81

 

41

 

-

Other investments, including loans(e)

 

2,187

 

2,090

 

-

 

82

 

15

Trade and other receivables(f)

 

2,713

 

7

 

758

 

-

 

1,948

 

 

11,030

 

5,246

 

839

 

123

 

4,822

Derivatives (net)

 

 

 

 

 

 

 

 

 

 

Forward contracts: designated as hedges(g)

 

(90)

 

-

 

-

 

(90)

 

-

Forward contracts and option contracts, not designated as hedges(g)

 

232

 

-

 

9

 

223

 

-

Derivatives related to net debt(h)

 

(310)

 

-

 

(310)

 

-

 

-

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

Trade and other payables

 

(5,175)

 

-

 

(20)

 

-

 

(5,155)

 

 

5,687

 

5,246

 

518

 

256

 

(333)

The table below shows the financial instruments carried at fair value by valuation method in accordance with IAS 39 at 31 December 2017:

 

 

 

 

 

 

 

 

 

 

 

Not held

 

 

Total

 

Level 1(a)(i)

 

Level 2(b)(i)

 

Level 3(c)(i)

 

at fair value

 

 

US$m

 

US$m

 

US$m

 

US$m

 

US$m

Assets

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents(d)

 

10,550

 

-

 

-

 

-

 

10,550

Investments in equity shares and funds

 

136

 

88

 

-

 

3

 

45

Other investments, including loans(e)

 

1,152

 

1,037

 

-

 

88

 

27

Trade and other receivables(f)

 

2,985

 

-

 

90

 

-

 

2,895

 

 

14,823

 

1,125

 

90

 

91

 

13,517

Derivatives (net)

 

 

 

 

 

 

 

 

 

 

Forward contracts and option contracts, not designated as hedges(g)

 

(87)

 

-

 

11

 

(98)

 

-

Derivatives related to net debt(h)

 

(177)

 

-

 

(177)

 

-

 

-

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

Trade and other payables

 

(5,922)

 

-

 

(15)

 

-

 

(5,907)

 

 

8,637

 

1,125

 

(91)

 

(7)

 

7,610

 

(a)

Valuation is based on unadjusted quoted prices in active markets for identical financial instruments. This category includes listed investments in equity shares and funds.

(b)

Valuation is based on inputs that are observable for the financial instruments; which include quoted prices for similar instruments or identical instruments in markets which are not considered to be active, or inputs, either directly or indirectly based on observable market data.

(c)

Valuation is based on inputs for the asset or liability that are not based on observable market data (unobservable inputs).

(d)

Cash and cash equivalents include money market funds which are treated as fair value through profit or loss (‘FVPL’) under IFRS 9 with the fair value movements going into finance income. Under IAS 39, these amounts were held at amortised cost.

(e)

Other investments, including loans, comprise: cash deposits in rehabilitation funds, government bonds, managed investment funds and royalty amounts receivable. The royalty receivables are valued based on an estimate of forward sales subject to the royalty agreement.

(f)

Trade receivables include provisionally priced receivables relating to sales contracts where the selling price is determined after delivery to the customer, based on the market price at the relevant quotation point stipulated in the contract. At 31 December 2017, under IAS 39, the quotational period exposure was considered to be an embedded derivative, which was separated from the host receivable and measured at fair value through the income statement. On adoption of IFRS 9, the embedded derivative is no longer separated and the entire balance is accounted for as one instrument and measured at fair value. At the end of June 2018, US$658 million of provisionally priced receivables were recognised.

(g)

Level 3 financial instruments, under IFRS 9, primarily consist of electricity purchase contracts linked to the LME with terms expiring between 2020 and 2030 (31 December 2017: 2018 and 2030). These contracts are measured using discounted cash flows and option model valuation techniques. These contracts with a net fair value of US$135 million at 30 June 2018 (31 December 2017: US$(98) million) are valued using significant unobservable inputs with regard to Aluminium prices.

Summary of changes in the fair value of Level 3 financial assets and financial liabilities

The table below shows the summary of changes in the fair value of the Group's Level 3 financial assets and financial liabilities for the six months to 30 June 2018 and the year ended 31 December 2017.

 

Level 3 Financial assets and liabilities

 

 

 

 

 

 

 

30 June

2018

 

31 December

2017

 

 

 

 

 

 

 

 

 

 

 

Opening balance

 

 

 

 

 

 

 

(7)

 

479

Adjustment from transition

 

 

 

 

 

 

 

19

 

-

Currency translation adjustments

 

 

 

 

 

 

 

(9)

 

8

Total realised gains/(losses) included in:

 

 

 

 

 

 

 

 

 

 

– Consolidated sales revenue

 

 

 

 

 

 

 

-

 

1

– Net operating costs

 

 

 

 

 

 

 

(1)

 

(5)

Total unrealised (losses)/gains included in:

 

 

 

 

 

 

 

 

 

 

– Consolidated sales revenue

 

 

 

 

 

 

 

(6)

 

17

– Net operating costs

 

 

 

 

 

 

 

145

 

(508)

Total unrealised gains transferred into other comprehensive income

 

 

 

 

 

 

 

93

 

-

Disposals/maturity of financial instruments

 

 

 

 

 

 

 

-

 

(5)

Transfers

 

 

 

 

 

 

 

22

 

6

Closing balance

 

 

 

 

 

 

 

256

 

(7)

Total gains/(losses) included in the income statement for assets and liabilities held at end of period

 

 

138

 

(491)